US-based AppYea has completed the previously announced acquisition of SleepX, a medical device company focused on sleep monitoring solutions.

SleepX’s lead product DreamIT is a wearable monitoring solution for the treatment of sleep apnea and snoring and improve the patients’ quality of life.

Upon completion of the acquisition, SleepX will become a fully owned subsidiary of AppYea, and will continue operating under its own brand name.

The combined company aims to focus on further development and marketing SleepX’s solution, including new investments and sales and marketing initiatives.

Also, SleepX is expected to commence a calibration study of its DreamIT.

AppYea chairman Boris Molchadsky said: “I am delighted that we have completed the acquisition of SleepX. The company develops a wearble technology solution to treat snoring and sleep apnea, which is patent protected in the US, EU and Israel, and caters to two growing markets in high demand.

“This aqisition allows us to execute our growth strategy towards the beginning of DreamIT’s marketing during the second half of 2022, while continuing its development with the Biomedical Department at Ben Gurion University in Israel, and launching our first calibaration trial.

“Meanwhile, we are examining the acquisition of other synergetic activities that will complement the SleepX vision to improve sleep quality and quality of life globally.”

SleepX said that it develops its solutions using a portfolio of AI and sensing technologies for the tracking, analysis, and diagnosis of vital signs during sleep time.

Its DreamIT solution is a patented wristband that communicates through its mobile app to gently vibrate with every breathing interruption.

The mobile app tracks sleep patterns using machine learning technology to simplify the treatment and recommend improvements based on user’s sleep and breathing patterns.

In addition to reducing snoring and improving sleep quality, the app also enables users to access statistics related to sleep patterns, to track and detect anomalies.

SleepX is developing its DreamIT solution with support from the Biomedical department of the Ben Gurion University of the Negev, and is patent protected in the US, EU and Israel.